Iberdomide in patients with systemic lupus erythematosus: a randomised, double-blind, placebo-controlled, ascending-dose, phase 2a study

• Victoria P Werth,
• Richard A Furie,
• Ying Ye,
• Xiaojiang Zhan,
• Peter H Schafer,
• Nikolay Delev,
• Shimon Korish,
• Michael Weiswasser,
• Douglas R Hough,
• Allison Gaudy

Affiliations

Victoria P Werth

Corporal Michael J Crescenz VA Medical Center, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA

Richard A Furie

Rheumatology, Northwell Health, Great Neck, New York, USA

Ying Ye

ICF Early Clinical Development, Bristol Myers Squibb, Princeton, New Jersey, USA

Xiaojiang Zhan

Biometrics, Bristol Myers Squibb, Princeton, New Jersey, USA

Peter H Schafer

TRC Inflammation, CV & Fibrosis and Global Health, Bristol Myers Squibb, Princeton, New Jersey, USA

Nikolay Delev

Clinical R&D, Bristol Myers Squibb, Princeton, New Jersey, USA

Shimon Korish

Clinical R&D, Bristol Myers Squibb, Princeton, New Jersey, USA

Michael Weiswasser

Clinical R&D, Bristol Myers Squibb, Princeton, New Jersey, USA

Douglas R Hough

Clinical Research, Bristol Myers Squibb, Princeton, New Jersey, USA

Allison Gaudy

Translational Development, Clinical Pharmacology, Bristol Myers Squibb, Princeton, New Jersey, USA